Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $75.44 USD
Change Today +0.32 / 0.43%
Volume 1.6M
DVA On Other Exchanges
Symbol
Exchange
New York
As of 4:15 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

davita healthcare partners i (DVA) Snapshot

Open
$75.28
Previous Close
$75.12
Day High
$75.82
Day Low
$74.83
52 Week High
04/27/15 - $85.17
52 Week Low
10/16/14 - $71.50
Market Cap
16.3B
Average Volume 10 Days
1.5M
EPS TTM
$3.67
Shares Outstanding
215.5M
EX-Date
--
P/E TM
20.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for DAVITA HEALTHCARE PARTNERS I (DVA)

davita healthcare partners i (DVA) Related Businessweek News

View More BusinessWeek News

davita healthcare partners i (DVA) Details

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company offers outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers, as well as patient and physician focused integrated health care delivery and management services. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2014, the company provided dialysis and administrative services in the United States through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia serving approximately 173,000 patients; operated or provided administrative services to a total of 91 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 7,200 patients; and integrated care management services for approximately 837,300 members under its care in southern California, central and south Florida, southern Nevada, central New Mexico, and central Arizona. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services in the United States. The company was formerly known as DaVita Inc. and changed its name to DaVita HealthCare Partners Inc. in November 2012. DaVita HealthCare Partners Inc. was founded in 1994 and is headquartered in Denver, Colorado.

57,900 Employees
Last Reported Date: 02/26/15
Founded in 1994

davita healthcare partners i (DVA) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $1.2M
Interim Chief Financial Officer and Chief Acc...
Total Annual Compensation: $650.0K
Chief Executive Officer of International and ...
Total Annual Compensation: $1.0M
Chief Executive Officer of Kidney Care Divisi...
Total Annual Compensation: $800.0K
Chief Legal Officer
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2014.

davita healthcare partners i (DVA) Key Developments

Davita Kidney Care Announces Formation of a Joint Venture Kidney Care Specialty Hospital Chain in Shandong Province China

DaVita Kidney Care announced it is forming a joint venture kidney care specialty hospital chain in Shandong province China. The agreement establishes DaVita (Shandong) Kidney Disease Hospital Co. Ltd. DaVita has the potential to significantly raise the quality of kidney care services available in this region of China. DaVita's partner in the joint venture is Xiaoyi Zhang, president of Shunjing Renal Hospital, the only private hospital approved for dialysis services in Jinan. Zhang comes to the new organization with more than a decade of experience leading large hospital organizations in Jinan, China.

DaVita HealthCare Partners Names Mark Price as President for its Healthcare Partners Colorado Market

DaVita HealthCare Partners announced it has named Mark Price as president for its HealthCare Partners Colorado market. Price previously worked for ChenMed where he led their Management Services Organization, Practice Management Resources (PMR) division.

DaVita HealthCare Partners Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

DaVita HealthCare Partners Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total net revenues of $3,434,618,000 against $3,172,489,000 a year ago. Operating income was $480,548,000 against $484,295,000 a year ago. Income before income taxes was $330,539,000 against $282,308,000 a year ago. Net income attributable to the company was $170,477,000 or $0.78 per diluted share against $147,683,000 or $0.68 per diluted share a year ago. Adjusted net income attributable to the company for the three months ended June 30, 2015 was $207 million, or $0.95 per share, excluding after-tax debt redemption charges of approximately $29 million, or $0.13 per share, and a tax adjustment related to the settlement of the Vainer private civil suit (the Vainer suit) of approximately $8 million, or $0.04 per share. Adjusted net income attributable to the company for the three months ended June 30, 2015, excluding the amortization of intangible assets associated with acquisitions and debt redemption charges, net of tax, and a tax adjustment related the settlement of the Vainer suit, was $233 million and adjusted diluted net income per share was $1.07.  For the six months, the company reported total net revenues of $6,722,583,000 against $6,215,265,000 a year ago. Operating income was $416,392,000 against $925,520,000 a year ago. Income before income taxes was $168,458,000 against $618,896,000 a year ago. Net income attributable to the company was $59,860,000 or $0.27 per diluted share against $330,972,000 or $1.53 per diluted share a year ago. Net cash provided by operating activities was $441,531,000 against $681,498,000 a year ago. Additions of property and equipment were $290,873,000 against $278,593,000 a year ago. Adjusted net income attributable to the company for the six months ended June 30, 2015 was $394 million, or $1.81 per share, excluding after-tax debt redemption charges and an after-tax settlement charge of $305 million, or $1.41 per share, related to the Vainer suit, which has been further updated for a tax adjustment related to the settlement of the Vainer suit of approximately $8 million, or $0.04 per share, in the second quarter of 2015. Adjusted operating income for the six months ended June 30, 2015 was $911 million, excluding a settlement charge of $495 million related to the Vainer suit. Adjusted net income attributable to the company for the six months ended June 30, 2015, excluding the amortization of intangible assets associated with acquisitions, the Vainer suit settlement charge, debt redemption charges, net of tax, a tax adjustment related to the settlement of the Vainer suit, was $446 million and adjusted diluted net income per share was $2.05. Consolidated net debt was $7,545,124,000 as on June 30, 2015. Net debt, net of cash and cash equivalents was $8,291 million as on June 30, 2015. For the year 2015, the company expects 2015 effective tax rate attributable to DaVita HealthCare Partners Inc. to be approximately 39.0% to 40.0%, excluding the Vainer suit settlement charge. The company updating the low end of consolidated operating income for 2015 to now is in the range of $1.825 billion to $1.925 billion. Previous consolidated operating income guidance for 2015 was in the range of $1.800 billion to $1.925 billion. The company updating the low end of operating income for Kidney Care for 2015 to now is in the range of $1.600 billion to $1.650 billion. Previous operating income guidance for Kidney Care for 2015 was in the range of $1.575 billion to $1.650 billion. The company still expects operating income for HCP for 2015 to be in the range of $225 million to $275 million. The company updating consolidated operating cash flow for 2015 to now be in the range of $1.600 billion to $1.750 billion. Previous consolidated operating cash flow for 2015 was in the range of $1.500 billion to $1.700 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVA:US $75.44 USD +0.32

DVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apollo Medical Holdings Inc $7.50 USD 0.00
Fresenius Medical Care AG & Co KGaA €68.92 EUR +2.00
Fresenius SE & Co KGaA €63.28 EUR +1.25
IPC Healthcare Inc $79.20 USD -0.30
Team Health Holdings Inc $58.09 USD -0.76
View Industry Companies
 

Industry Analysis

DVA

Industry Average

Valuation DVA Industry Range
Price/Earnings 36.2x
Price/Sales 1.2x
Price/Book 3.1x
Price/Cash Flow 15.2x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAVITA HEALTHCARE PARTNERS I, please visit www.davita.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.